A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older
Latest Information Update: 07 Aug 2021
Price :
$35 *
At a glance
- Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 17 Jun 2021 Results of an exposure-efficacy pooled analysis from three clinical studies: NCT01814826, NCT02782468 and NCT02610777 assessing impact of Pevonedistat exposure on efficacy and safety presented at the 26th Congress of the European Haematology Association
- 08 Jun 2021 Results of pooled analysis from 3 studies (NCT01814826, NCT02782468 and NCT02610777) were used evaluate the impact of PEV exposure on safety and efficacy, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 29 Jul 2019 A population pharmacokinetic analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat pharmacokinetics using pooled data from 6 clinical studies ; results published in the British Journal of Clinical Pharmacology